Automate Your Wheel Strategy on BBLGW
With Tiblio's Option Bot, you can configure your own wheel strategy including BBLGW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBLGW
- Rev/Share 0.0
- Book/Share 11.8254
- PB 0.181
- Debt/Equity 0.0
- CurrentRatio 17.2408
- ROIC -0.6507
- MktCap 3435256.0
- FreeCF/Share -5.9353
- PFCF -1.0376
- PE -0.2828
- Debt/Assets 0.0
- DivYield 0
- ROE -1.0059
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Bone Biologics Corporation (BBLGW)
- IPO Date 2021-10-13
- Website http://www.bonebiologics.com
- Industry Medical - Devices
- CEO Jeffrey Frelick
- Employees 2
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.